Anti-OX40 Antibody Formulation for Aggregation and Precipitation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antibodies against the human OX40 receptor, such as monoclonal anti-OX40 antibodies, are prone to chemical and physical degradation, leading to denaturation, aggregation, and precipitation, which affects their stability, bioactivity, and safety.
Innovation Solution
A stable pharmaceutical formulation comprising a monoclonal anti-OX40 antibody or its antigen-binding fragment, combined with a buffer, a stabilizer, and a surfactant, optimized for pH, concentration, and composition to enhance stability and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If monoclonal anti-OX40 antibody is formulated without stabilizers and surfactants, then the formulation is simple, but the antibody undergoes denaturation, aggregation, and precipitation
Solution Approach 1:
The patent introduces stabilizers (such as sugars, polyols, or amino acids) and surfactants as intermediary substances that mediate between the antibody and the aqueous environment. These intermediaries protect the antibody from direct exposure to destabilizing conditions, preventing denaturation, aggregation, and precipitation while maintaining formulation simplicity through selective use of proven excipients
2Quantity of substance
If the antibody concentration is increased to reduce dosage volume, then the therapeutic efficacy is improved, but the aggregation and precipitation tendency increases
Solution Approach 1:
The patent optimizes the antibody concentration parameter within a specific range (5-100 mg/mL, preferably 10-50 mg/mL) and combines it with adjusted stabilizer and surfactant concentrations. This parameter optimization allows achieving high therapeutic efficacy through reduced dosage volume while preventing aggregation and precipitation through coordinated excipient levels
3Stability of the object's composition
If the pH is adjusted to optimize antibody stability, then the denaturation is reduced, but the precipitation may occur due to hydrophobicity changes
Solution Approach 1:
The patent adjusts the pH parameter to a specific range (pH 5.0-8.0, preferably pH 6.0-7.5) that optimizes antibody stability by minimizing denaturation. This pH optimization is combined with surfactant selection and concentration adjustment to counteract hydrophobicity changes, thereby preventing precipitation while maintaining the antibody in a stable, soluble state
4Device complexity
If no surfactant is added to the formulation, then the formulation complexity is reduced, but the immunogenic reactions and bioactivity loss increase
Solution Approach 1:
The patent introduces surfactants as intermediary substances that interact with hydrophobic regions of the antibody, preventing exposure of these regions to the aqueous environment and immune system. This intermediary action reduces immunogenic reactions and bioactivity loss while maintaining formulation simplicity through use of well-characterized surfactants at optimized concentrations
Data Source
AI summary
Disclosed is a pharmaceutical formulation including a monoclonal OX40 antibody, a buffer, a stabilizer, and a surfactant, which can maintain the stability under various scenarios, such as manufacturing, packaging, sub-packaging, shipping, administration, and/or storage. Also disclosed are the use of the pharmaceutical formulation in the preparation of a drug for treating OX40-associated diseases, in particular, inflammatory and/or autoimmune diseases, and a method for preparing the pharmaceutical formulation.